Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hesse, Truly fantastic returns this year to date. Don't be beating on yourself (message to smurf also - and others) about this last month.
As you mentioned before, preserving capital is important first and foremost, then making $$$.
Down 1.5k for a month in which the IBB went down 20% or so is good. Remember to stay to your core values/plan as you have good ones IMO.
Keep that watchlist updated in your mind and stay focused on the short term catalysts (reminding myself also). As Smurf and I and you and others have all noted, things have changed at the moment, and buying for 3 months down the road doesn't seem the case for Bios. Shorten the timeframe perhaps, that's what I'm looking to do once I get back out from under current holdings.
Also remember to play only the ones that you have been watching for a while. Those seem to do the best for you IMO.
Good Job. Hope lil Sam is doing well.
NAVB - I believe it has two catalysts? Two PDUFA's? Not that - that matters in the market at the moment, but is good for support perhaps. On watch.
MSTX - $.585 - Looks interesting. Is always on watch for me. Still watching it at times, but not super close. Need to find about about upcoming catalysts again.
INO - $2.39 - I like this one Azy. Only looking at the charts and not knowing anything more, the 15 Min chart looks good for the next day or so and the Daily Chart looks ready to move with any help from the IBB and Bio sector.
200 DMA at $2.39, so seems like offering downside support and MACD looking ready to cross, but hasn't yet - so may take a few days still. May not be quite ready yet but looks close if it can get volume like you mentioned, and/or Bio sector offers movement up.
Best of Luck with it.
INO - $2.39 - I like this one Azy. Only looking at the charts and not knowing anything more, the 15 Min chart looks good for the next day or so and the Daily Chart looks ready to move with any help from the IBB and Bio sector.
200 DMA at $2.39, so seems like offering downside support and MACD looking ready to cross, but hasn't yet - so may take a few days still. May not be quite ready yet but looks close if it can get volume like you mentioned, and/or Bio sector offers movement up.
Best of Luck with it.
Thanks. I thought I heard 3 days too, but wasn't sure which events those were. I wonder if company's think though about posting the info a day or two apart if possible, or if that's of no concern to them.
ACHN - Two PR's in one today. From an investor standpoint, I'd rather have the company PR one, then wait a few days and PR the other. I wonder if company's ever think of that? Are they obligated to PR within a certain timeframe???
Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug -
- Initiated Phase 2 Study Evaluating ACH-3102, Second-Generation NS5A Inhibitor, With Sofosbuvir for 8 Weeks of Treatment or Less in Genotype 1 HCV Treatment-Naïve Patients -
Thanks. Oh, I got clobbered good. Down 7K I think it is. Was my first event hold through that missed to date. I still liked the reasons holding for it. I just have to risk/reward better.
At this point, I plan on sneaking out of it somehow with a 3-4K loss at some point. Or hope so. Either average down, or wait it out or hope for a Green fairy to fly in and sprinkle $$ dust.
Will get back to you on the BIO sector stabilizing. I saw a great tweet the other day that had a graphic in it that I saved. Just need to find and post it. It mentioned the bounceback % of the Bios after the last 5-10 corrections.
One of the things that's needed is...some wins! After the Bio correction, if I'm not mistaken POZN was the first up, all eyes on it, failure, then CYTK failure, then SYN now (and I think a few more I missed). The ones that have had good data, seem to sell off even quicker then usual. SGYP, etc.
We need some ridiculous PDUFA, ADCOM, data trial price pops to get everyone real greedy again and thinking that they're missing out :)
Nope. Still holding and nursing the wound. Is a lot of info and misinformation abounding. The 12 month data looked good and the 24 month data was also decent, just not stat significant I guess. It's confusing as from what i've read so far, copaxone takes 8-9 months to kick in, so if it shows great results in the 12 month trial, then that should be really attributed to estriol moreso and copaxone. Then the 24 month might be misleading because in the months of 10-24, the copaxone kicks in more and it wouldn't show as much of a difference.
I don't think I'm explaining it well, and it all may be moot anyway. But I guess my point is, it had good 12 month data and they may be able to partner with someone somehow and have a few other things in the pipeline. All mumbo jumbo speak for...am looking for answers :)
This is one of those where, the results seem good for patients, just not good for the markets and is a bad time for Bios still.
I'll have good trades and bad ones. Risk/reward. Will examine this one a lot later when its all said and done. Until then, back to business and find some more winners and of course...
Go ELTP !
Glad to hear all is well for you. Things can be replaced (so can stock losses - and as we've learned - gains too :(
Tomorrow is another day - Hopefully uneventful - except for GREEN!
Good Vibes towards Andrew. Folks, send some good vibes, happy thoughts, and prayers towards AndrewLee's way as there's a very large 200 acre fire very near his place.
Hoping for the best for him and anyone else affected.
Still another presentation this afternoon. For what that's worth...(after hours presentation)
American Academy of Neurology - Rhonda Voskuhl, M.D. - Topline Phase II Trimesta Results for Relapsing-Remitting MS
Tuesday, April 29, 2014 - Wednesday, April 30, 2014
Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:
MS and CNS Inflammatory Disease: Novel Therapeutics
Presentation: 003
Event Date: Tuesday, April 29, 2014
Presentation Time: 3:45 p.m. (ET)
Emerging Therapeutic Advances in Multiple Sclerosis
Presentation: 002
Event Date: Wednesday, April 30, 2014
Presentation Time: 5:35 p.m. (ET)
thank you - much appreciated.
willlbone, just curious as to what you used as your entrance and exit indicators?
Thanks. Always trying to learn.
nice play
Gotta do what you're comfortable with and what works for you. My game plan is still in place, just need to adjust it a bit at times and learn, and as always "LOCK IN PROFITS"
Let's see if the overall markets can take the next leg up, that will help.
SYN: $1.40 - Dropped to $1.25 for a few seconds, stood at $1.30 for a large order and then moved up.
On the Daily chart the problem that I have adding at these levels is that the Full Stochastic isn't in very oversold area yet. That doesn't necessarily mean it can't rebound now, but in theory, for me at least, if its oversold, then I'd like all 3 of my indicators that I use most to show it. RSI just hit 26.
Am just watching still. Waiting for double bottom confirmation of sorts. May wait a few days before entering, not sure really. I can wait.
So, Go ELTP :)
SYN Daily:
SYN: $1.40 - Yup - She's tanking mighty bad. Now comes the figuring out where she bottoms, and when.
SYN $1.71 - Am thinking about the trade and what I should have done differently. Based upon how the data was dropped, when it was dropped, how fast it moved, mass confusion, etc. I'm not sure as of yet.
The only thing I know I should have done was to lighten up a bit and sell 1,000 of my 4,000 shares, so in case of bad news, I could then use that extra to average down. I read a post like that from someone else who did just that before the news was announced. That would have helped me more going forward.
Win some, lose some, as long as you win more than lose, that's the plan. I felt good about it for a variety of reasons, and knew the risk. I will think about it more and try and learn from it. Then again, sometimes, just is what it is and you roll with punches and get them next time.
SYN: Hard to pass up sometimes when you do have the cash. Good for you for acting quickly though hesse afterwards. Was a very confusing time with the price bouncing around like crazy.
SYN: IMO, Was a combination of events - all leading to mass confusion and spin by the company and yes, not meeting all endpoints.
they did well on the 12 month, but missed on the 24 month. The reasons for that could be many.
They didn't halt the stock at 3:45ish yesterday, just dropped the news with 10 mins or less in the stock day. Why the heck do you put it out at 10 mins left? I read some suggestions that it was the Dr. from UCLA's study that had been going on for years, so they wanted to let her present it all, and her presentation was at that time. Yeah, whatever. You could have still PR'd earlier in the day and let her still look like the Queen of it all.
Then the PR was worded as positive data, when in fact although it may be positive in their minds, it wasn't in the market's eyes. They left out the "meeting primary endpoints" and additional data in the PR from what I read. The 12 month looked good. From a patient standpoint, I'd take it. From a market standpoint, that's a different idea I guess.
Waiting game for now. We'll see if panic subsides and if it starts to look attractive again, or if peeps have said "enough is enough" and moved on.
well, let's hope for more of those for you :)
IPCI - Was there any news or was it just one of those, "ummmm - what the heck just happened?" moments?
Bio Sentiment Watch: FOLD $2.16 - Yesterday Good news. Pops 30% on open - Holds there around 15 mins, then fades all day. Down 2% Today in early action.
I'm just continuing to watch - to get a feel of how the Bios are reacting now in this - "Does the market still like Bios?" times.
----------------------------------
link: http://www.valuewalk.com/2014/04/amicus-therapeutics-inc-fold-soars-on-positive-results/
According to Amicus Therapeutics, Inc. (NASDAQ:FOLD), patients who switched from placebo to migalastat after month 6 demonstrated a statistically significant reduction in kidney interstitial capillary GL-3 (p=0.013) on month 12. Those who remained on migalastat for 12 months experienced a durable reduction kidney interstitial capillary GL-3.
The biopharmaceutical company said reduction in disease substrate was observed in plasma lyso-Gb3 in patients who switched from placebo to migalstat (p< 0.0001).
Amicus Therapeutics, Inc. (NASDAQ:FOLD) said kidney function (estimated glomerular filtration rate (eGFR), iohexol mGFR) remained stable over 18-24 months and migalastat was well tolerated by patients and was generally safe. According to the company, 85% or 35 of the 41 subjects with GLP HEK amenable mutations who completed the Study 011 remained in the voluntary extension study.
Bio Sentiment Watch: SGYP $4.85 - Good Trial Results - Basically flat after selloff. Best time to sell, Premarket or seconds after the open. (so far).
link: http://finance.yahoo.com/news/synergy-pharmaceuticals-announces-positive-results-100000266.html
Synergy Pharmaceuticals Inc. (SGYP) today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C). The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Synergy is pleased to report this trial has achieved that objective.
SYN - $.186 - Am holding for now. Will see how this settles and/or moves and whether or not to average down later. I'm a patient man when I need to be.
I heard parts of the conference call. From what I heard, from a common sense "did it work?" standpoint, everything was well regarded and there's a lot of interest in the study and results.
The 24 month did not meet its primary endpoint and they mentioned that the 24 month was only an "exploratory" trial. I believe that's mumbo jumbo speak for we didn't get the results we wanted, but in our Phase III which we are now planning on doing, we'll add more patients and set this up so it'll be a winner.
They mentioned that they would probably use 250-300 patients for a new study which should "quite easily" meet the endpoints, as this 24 month was not setup correctly to do so. (yada yada).
They mentioned that they are planning to move forward and are in partnership talks with many, yada yada yada, as expected. No questions about why they cancelled their equity agreement that they had.
They did meet the 12 month and results look good for that IMO. But market wants what market wants and as such, I'm holding for now. They mentioned something about a cognitive trail also.
They also mentioned that their last patient follow up will be in June for this study.
Holding...for now.
SYN - Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET--
link: http://finance.yahoo.com/news/synthetic-biologics-discuss-phase-ii-105800747.html
ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Topline data were announced yesterday by the University of California, Los Angeles (UCLA) School of Medicine and presented at the 66th Annual Meeting of the American Academy of Neurology by the study's lead investigator, Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA David Geffen School of Medicine.
View photo
.Synthetic Biologics, Inc. Logo.
In this Phase II study, women receiving oral Trimesta plus injectable Copaxone® demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment compared to women receiving placebo plus Copaxone (p=0.0306), and a 32 percent decrease in annualized relapse rate at 24 months (p=0.1527). Patients in both treatment arms demonstrated improved scores on the Expanded Disability Status Scale (EDSS) compared to baseline. Cognitive function test scores, as measured by the Paced Auditory Serial Addition Test (PASAT), in women receiving Trimesta plus Copaxone also improved compared to baseline and were significantly different from placebo plus Copaxone at 12 months.
Treatment was generally safe and well tolerated. There were 21 serious adverse events (9 in the Trimesta plus Copaxone group and 12 in the placebo plus Copaxone group). Adverse events were typically mild in nature and balanced between treatment groups except for an increase in irregular menses in patients who received Trimesta.
The investigator-initiated, Phase II, two-year, multi-center, randomized, double-blinded, placebo-controlled (1:1) study evaluated Trimesta as an oral, once-daily dose of 8 mg per day plus Copaxone in women with RRMS, aged 18-50 years. At randomization, of the 158 women enrolled across 16 clinical sites in the United States, 99.4 percent had at least one relapse in the preceding 24 months.
Dr. Voskuhl's work is supported by grants exceeding $8 million, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS's Southern California chapter, and the National Institutes of Health (NIH). UCLA and the NIH issued concurrent press releases April 29, 2014.
Conference Call
Jeffrey Riley, Chief Executive Officer, and Joe Sliman, Senior Vice President, Clinical & Regulatory Affairs, of Synthetic Biologics, Inc. will host a conference call to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol).
Interested parties should call 1-877-870-4263, (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1-412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet with a slide presentation at http://www.videonewswire.com/event.asp?id=99175. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=99175 for 60 days after the call.
SYN - Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET--
link: http://finance.yahoo.com/news/synthetic-biologics-discuss-phase-ii-105800747.html
ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Topline data were announced yesterday by the University of California, Los Angeles (UCLA) School of Medicine and presented at the 66th Annual Meeting of the American Academy of Neurology by the study's lead investigator, Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA David Geffen School of Medicine.
View photo
.Synthetic Biologics, Inc. Logo.
In this Phase II study, women receiving oral Trimesta plus injectable Copaxone® demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment compared to women receiving placebo plus Copaxone (p=0.0306), and a 32 percent decrease in annualized relapse rate at 24 months (p=0.1527). Patients in both treatment arms demonstrated improved scores on the Expanded Disability Status Scale (EDSS) compared to baseline. Cognitive function test scores, as measured by the Paced Auditory Serial Addition Test (PASAT), in women receiving Trimesta plus Copaxone also improved compared to baseline and were significantly different from placebo plus Copaxone at 12 months.
Treatment was generally safe and well tolerated. There were 21 serious adverse events (9 in the Trimesta plus Copaxone group and 12 in the placebo plus Copaxone group). Adverse events were typically mild in nature and balanced between treatment groups except for an increase in irregular menses in patients who received Trimesta.
The investigator-initiated, Phase II, two-year, multi-center, randomized, double-blinded, placebo-controlled (1:1) study evaluated Trimesta as an oral, once-daily dose of 8 mg per day plus Copaxone in women with RRMS, aged 18-50 years. At randomization, of the 158 women enrolled across 16 clinical sites in the United States, 99.4 percent had at least one relapse in the preceding 24 months.
Dr. Voskuhl's work is supported by grants exceeding $8 million, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS's Southern California chapter, and the National Institutes of Health (NIH). UCLA and the NIH issued concurrent press releases April 29, 2014.
Conference Call
Jeffrey Riley, Chief Executive Officer, and Joe Sliman, Senior Vice President, Clinical & Regulatory Affairs, of Synthetic Biologics, Inc. will host a conference call to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol).
Interested parties should call 1-877-870-4263, (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1-412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet with a slide presentation at http://www.videonewswire.com/event.asp?id=99175. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=99175 for 60 days after the call.
SYN: Am holding still. Will see if sentiment changes tonight and going into tomorrow's presentation.
I missed where you bought in today :(
I did not sell as of yet. I may buy some AH to average down.
SNY: Well that sucked. I saw the PR about positive news, scanned it quick and then went off to pick up the kids from school, came home and did one of those, "what you talking about willis?" looks.
all left to say is "GO ELTP!"
there's good days, and bad days, tomorrow is another day :)
They have another presentation tomorrow. Perhaps it'll make a comeback of sorts.
ADMP sure has low volume days. Should move fast on any news.
And thanks.
NVAX is the one that I need to find out more from hesse about as I believe that's the one with the large amount of insiders buying recently. Good for him.
Trying to wait patiently for all my holdings to eventually pop back to even or more. I waited out RGDX and ETRM, so now 3 to go with SYN, IDRA, and ELTP. I have faith in all three. Just need to wait it out, and if one pops, then hope to use that to average down. Pretty much like a lot of folks here playing Bios I suspect.
Norm, Its interesting that even with the catalyst so soon, that SYN is moving right with the IBB still in peaks and valleys and not more of a smoothing/less movement.
Let's keep our fingers crossed for good news.
ADMP - Thanks for update. I'll be watching this one and also looking for an entry when I have available cash.
IDRA $2.82 - Added 500 @ $2.83 and 500 @ $2.70 today. Average now $3.51.
SYN: Data due this week for top-line data from its Trimesta/Copaxone combo Phase II multi-center clinical trial, any time from now until Presentation on Tuesday/Wednesday afternoon.
Data may be PR'd anytime now since the embargo that the AAN had which prevented early data releases, expired on Friday. As some may know CYTK is also going to be presenting at AAN. CYTK announced failed results on Friday before the market opened. Their stock plummeted 64% on Friday.
SYN's stocked dropped on Friday. So did the market and many bios. There was a email sent out by Seeking Alpha which mistakenly stated that SYN was having a reverse stock split. It was not SYN, it was another company with a similar symbol. Also, I believe that $heff sold his remaining shares on an automatic stop loss.
SYN has made a nice recovery lately from the Bio selloff. It would be understandable that anyone who saw the CYTK failed results and stock price drop would be anxious and might sell some, or all just in case of bad data.
At the moment, I'm holding 4,000 shares. SYN didn't PR failed results on Friday, even though they had the opportunity as well. That doesn't mean that they will have positive results this week. But perhaps it does push it in its favor a little. I read a post this week that PGNX presented failed data at a presentation once. I don't know if that's true and wasn't able to verify. So, who knows?
At the moment, I plan on holding all my shares through data release, whenever that may be. My plans may change at any moment. SYN recently cancelled an equity agreement in which they could have raised cash.
For anyone interested in SYN and one of its investor's; Randall Kirk, here's some good info: http://stockmatusow.com/following-the-smart-money-the-small-cap-biotech-investments-of-randal-j-kirk/ (scroll down page for SYN section).
Best of Luck and thoughts always appreciated. I have no price targets if data is good, except that it should be above what it is now.
-------------------------------------------
SYN is presenting at the American Academy of Neurology:
American Academy of Neurology - Rhonda Voskuhl, M.D. - Topline Phase II Trimesta Results for Relapsing-Remitting MS
Tuesday, April 29, 2014 - Wednesday, April 30, 2014
Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:
MS and CNS Inflammatory Disease: Novel Therapeutics
Presentation: 003
Event Date: Tuesday, April 29, 2014
Presentation Time: 3:45 p.m. (ET)
Emerging Therapeutic Advances in Multiple Sclerosis
Presentation: 002
Event Date: Wednesday, April 30, 2014
Presentation Time: 5:35 p.m. (ET)
No webcast available.
POZN - CRL was after - after hours trading closed. There was no info officially released all trading day about it, only rumors of investors relation stating a PR would be out yesterday. I was watching the price to see if it was going to fall like it did in after hours with CHTP. It did a little, but not really much. These things never make sense.
Little bit of history:
CHTP:
On PDUFA day, the FDA published 2-3 hour delays on their web site due to massive snowstorm and listed the day as an optional day for their employees to take a day off or work from home. It would be logical that there might be a delay or it might not be done.
No PDUFA news during the day, stock price plummeted ala bear raid, CHTP went out of its way to issue a PR stating that they had NOT received any news from the FDA, price recovered. Stock is halted a few times during the day. After hours occurred. No news - another massive bear raid. Then an hour before AH trading closes, CHTP issues a PR stating that the FDA would delay the decision until next week. Price rallies, then falls a little.
Then I believe Monday was market closed and Tuesday CHTP no news issued during the day until late in the day. (i think it was after hours) - so a lot of waiting. Approved. Price rallies, then sells off like most that are approved.
POZN:
No news during the day, price opens up, falls all day, but so did the market and most bios. After hours, still no news. Price falls, but not really all that much and on low volume. Twitterverse thinks CRL. An hour AFTER - after hours trading closes, POZN issues PR stating its a CRL for manufacturing issues and issues this PR; link: http://finance.yahoo.com/news/pozen-pa8140-pa32540-receives-complete-003000785.html
“Although we were hopeful for a first cycle approval, we believe that the issues raised during the inspection can be remedied to the satisfaction of the FDA. The timing of the inspection of this facility was unfortunate as the final inspection report was only issued today. Because it occurred so close to our PDUFA date, there was no opportunity to address the issues raised,” said John R. Plachetka, Chairman, President and Chief Executive Officer.
------------------------------------
Its just my opinion, but I believe the POZN didn't get the CRL at 8PM after hours. I believe they received it earlier in the day and waited to put it out. By putting it out after hours, and on Friday night, its somewhat buried in the news for most people. Not buried of course for anyone invested in it.
I may be wrong, but I believe they held the info from sometime earlier in the day. Just my $.02 and always watching for patterns.
ETRM $1.78 - I personally am not going to re-enter ETRM until it gets closer to its date and / or dips down to the $1.50-$1.60 area.
If it doesn't fall that far down, so be it, and I'll re-evaluate later. ETRM's STOCH is possibly turning down along with the other indicators. Of course, it's following the sector too, so that has to be always watched.
The key question for ETRM IMO is whether the ATM has finally been completed. It was nearing the remaining 1/4 I believe, last time I read.